Missense mutation R1066C in the second transmembrane domain of cftr causes a severe cystic fibrosis phenotype

Study of 19 heterozygous and 2 homozygous patients

T. Casals, P. Pacheco, C. Barreto, J. Giménez, M. D. Ramos, S. Pereira, J. A. Pinheiro, N. Cobos, A. Curvelo, C. Vázquez, H. Rocha, J. L. Séculi, E. Pérez, J. Dapena, E. Carrilho, A. Duarte, A. M. Palacio, V. Nunes, J. Lavinha, Xavier P. Estivill

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

We report the clinical features of 21 unrelated cystic fibrosis (CF) patients from Portugal and Spain, who carry the mutation R1066C in the CFTR gene. The current age of the patients was higher in the R1066C/any mutation group (P < 0.01), as compared to the ΔF508/ΔF508 group. Poor values for lung radiological involvement (Chrispin-Norman) and general status (Shwachman-Kulcycki) were observed in the R1066C/any mutation group (P < 0.005 and P < 0.0004). A slightly, but not significantly worse lung function was found in the R1066C/any mutation group when compared with the ΔF508/ΔF508 patients. No significant differences were detected regarding the age at diagnosis, sweat Cl- values, or percentiles of height and weight between the two groups. Neither were significant differences observed regarding sex, meconium ileus (4.7% vs. 11.1%), dehydration (10.5% vs. 14.7%), or pancreatic insufficiency (PI) (100% vs. 97.8%). The proportion of patients with lung colonization by bacterial pathogens was slightly, but not significantly higher in the R1066C/any mutation group (70.0%), as compared with the ΔF508/ΔF508 group (57.5%). Other clinical complications were significantly more frequent in the R1066C/any mutation patients (P < 0.02) than in the ΔF508/ΔF508 group. The two homozygous R1066C/R1066C patients died at the ages of 3 months and 7 years. The data presented in this study clearly demonstrate that the R1066C mutation is responsible for a severe phenotype similar to that observed in homozygous ΔF508 patients. The poor clinical scores and complications of patients with the R1066C mutation are probably related to their slightly longer survival.

Original languageEnglish
Pages (from-to)387-392
Number of pages6
JournalHuman Mutation
Volume10
Issue number5
DOIs
Publication statusPublished - 1997
Externally publishedYes

Fingerprint

Missense Mutation
Cystic Fibrosis
Phenotype
Mutation
Lung
Exocrine Pancreatic Insufficiency
Meconium
Portugal
Ileus
Sweat
Dehydration
Spain
Weights and Measures
Survival
Genes

Keywords

  • Cystic fibrosis
  • Genotype/phenotype correlation
  • R1066C mutation

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)

Cite this

Missense mutation R1066C in the second transmembrane domain of cftr causes a severe cystic fibrosis phenotype : Study of 19 heterozygous and 2 homozygous patients. / Casals, T.; Pacheco, P.; Barreto, C.; Giménez, J.; Ramos, M. D.; Pereira, S.; Pinheiro, J. A.; Cobos, N.; Curvelo, A.; Vázquez, C.; Rocha, H.; Séculi, J. L.; Pérez, E.; Dapena, J.; Carrilho, E.; Duarte, A.; Palacio, A. M.; Nunes, V.; Lavinha, J.; Estivill, Xavier P.

In: Human Mutation, Vol. 10, No. 5, 1997, p. 387-392.

Research output: Contribution to journalArticle

Casals, T, Pacheco, P, Barreto, C, Giménez, J, Ramos, MD, Pereira, S, Pinheiro, JA, Cobos, N, Curvelo, A, Vázquez, C, Rocha, H, Séculi, JL, Pérez, E, Dapena, J, Carrilho, E, Duarte, A, Palacio, AM, Nunes, V, Lavinha, J & Estivill, XP 1997, 'Missense mutation R1066C in the second transmembrane domain of cftr causes a severe cystic fibrosis phenotype: Study of 19 heterozygous and 2 homozygous patients', Human Mutation, vol. 10, no. 5, pp. 387-392. https://doi.org/10.1002/(SICI)1098-1004(1997)10:5<387::AID-HUMU9>3.0.CO;2-C
Casals, T. ; Pacheco, P. ; Barreto, C. ; Giménez, J. ; Ramos, M. D. ; Pereira, S. ; Pinheiro, J. A. ; Cobos, N. ; Curvelo, A. ; Vázquez, C. ; Rocha, H. ; Séculi, J. L. ; Pérez, E. ; Dapena, J. ; Carrilho, E. ; Duarte, A. ; Palacio, A. M. ; Nunes, V. ; Lavinha, J. ; Estivill, Xavier P. / Missense mutation R1066C in the second transmembrane domain of cftr causes a severe cystic fibrosis phenotype : Study of 19 heterozygous and 2 homozygous patients. In: Human Mutation. 1997 ; Vol. 10, No. 5. pp. 387-392.
@article{b250cea2c6e0457bb7722d569d806d52,
title = "Missense mutation R1066C in the second transmembrane domain of cftr causes a severe cystic fibrosis phenotype: Study of 19 heterozygous and 2 homozygous patients",
abstract = "We report the clinical features of 21 unrelated cystic fibrosis (CF) patients from Portugal and Spain, who carry the mutation R1066C in the CFTR gene. The current age of the patients was higher in the R1066C/any mutation group (P < 0.01), as compared to the ΔF508/ΔF508 group. Poor values for lung radiological involvement (Chrispin-Norman) and general status (Shwachman-Kulcycki) were observed in the R1066C/any mutation group (P < 0.005 and P < 0.0004). A slightly, but not significantly worse lung function was found in the R1066C/any mutation group when compared with the ΔF508/ΔF508 patients. No significant differences were detected regarding the age at diagnosis, sweat Cl- values, or percentiles of height and weight between the two groups. Neither were significant differences observed regarding sex, meconium ileus (4.7{\%} vs. 11.1{\%}), dehydration (10.5{\%} vs. 14.7{\%}), or pancreatic insufficiency (PI) (100{\%} vs. 97.8{\%}). The proportion of patients with lung colonization by bacterial pathogens was slightly, but not significantly higher in the R1066C/any mutation group (70.0{\%}), as compared with the ΔF508/ΔF508 group (57.5{\%}). Other clinical complications were significantly more frequent in the R1066C/any mutation patients (P < 0.02) than in the ΔF508/ΔF508 group. The two homozygous R1066C/R1066C patients died at the ages of 3 months and 7 years. The data presented in this study clearly demonstrate that the R1066C mutation is responsible for a severe phenotype similar to that observed in homozygous ΔF508 patients. The poor clinical scores and complications of patients with the R1066C mutation are probably related to their slightly longer survival.",
keywords = "Cystic fibrosis, Genotype/phenotype correlation, R1066C mutation",
author = "T. Casals and P. Pacheco and C. Barreto and J. Gim{\'e}nez and Ramos, {M. D.} and S. Pereira and Pinheiro, {J. A.} and N. Cobos and A. Curvelo and C. V{\'a}zquez and H. Rocha and S{\'e}culi, {J. L.} and E. P{\'e}rez and J. Dapena and E. Carrilho and A. Duarte and Palacio, {A. M.} and V. Nunes and J. Lavinha and Estivill, {Xavier P.}",
year = "1997",
doi = "10.1002/(SICI)1098-1004(1997)10:5<387::AID-HUMU9>3.0.CO;2-C",
language = "English",
volume = "10",
pages = "387--392",
journal = "Human Mutation",
issn = "1059-7794",
publisher = "Wiley-Liss Inc.",
number = "5",

}

TY - JOUR

T1 - Missense mutation R1066C in the second transmembrane domain of cftr causes a severe cystic fibrosis phenotype

T2 - Study of 19 heterozygous and 2 homozygous patients

AU - Casals, T.

AU - Pacheco, P.

AU - Barreto, C.

AU - Giménez, J.

AU - Ramos, M. D.

AU - Pereira, S.

AU - Pinheiro, J. A.

AU - Cobos, N.

AU - Curvelo, A.

AU - Vázquez, C.

AU - Rocha, H.

AU - Séculi, J. L.

AU - Pérez, E.

AU - Dapena, J.

AU - Carrilho, E.

AU - Duarte, A.

AU - Palacio, A. M.

AU - Nunes, V.

AU - Lavinha, J.

AU - Estivill, Xavier P.

PY - 1997

Y1 - 1997

N2 - We report the clinical features of 21 unrelated cystic fibrosis (CF) patients from Portugal and Spain, who carry the mutation R1066C in the CFTR gene. The current age of the patients was higher in the R1066C/any mutation group (P < 0.01), as compared to the ΔF508/ΔF508 group. Poor values for lung radiological involvement (Chrispin-Norman) and general status (Shwachman-Kulcycki) were observed in the R1066C/any mutation group (P < 0.005 and P < 0.0004). A slightly, but not significantly worse lung function was found in the R1066C/any mutation group when compared with the ΔF508/ΔF508 patients. No significant differences were detected regarding the age at diagnosis, sweat Cl- values, or percentiles of height and weight between the two groups. Neither were significant differences observed regarding sex, meconium ileus (4.7% vs. 11.1%), dehydration (10.5% vs. 14.7%), or pancreatic insufficiency (PI) (100% vs. 97.8%). The proportion of patients with lung colonization by bacterial pathogens was slightly, but not significantly higher in the R1066C/any mutation group (70.0%), as compared with the ΔF508/ΔF508 group (57.5%). Other clinical complications were significantly more frequent in the R1066C/any mutation patients (P < 0.02) than in the ΔF508/ΔF508 group. The two homozygous R1066C/R1066C patients died at the ages of 3 months and 7 years. The data presented in this study clearly demonstrate that the R1066C mutation is responsible for a severe phenotype similar to that observed in homozygous ΔF508 patients. The poor clinical scores and complications of patients with the R1066C mutation are probably related to their slightly longer survival.

AB - We report the clinical features of 21 unrelated cystic fibrosis (CF) patients from Portugal and Spain, who carry the mutation R1066C in the CFTR gene. The current age of the patients was higher in the R1066C/any mutation group (P < 0.01), as compared to the ΔF508/ΔF508 group. Poor values for lung radiological involvement (Chrispin-Norman) and general status (Shwachman-Kulcycki) were observed in the R1066C/any mutation group (P < 0.005 and P < 0.0004). A slightly, but not significantly worse lung function was found in the R1066C/any mutation group when compared with the ΔF508/ΔF508 patients. No significant differences were detected regarding the age at diagnosis, sweat Cl- values, or percentiles of height and weight between the two groups. Neither were significant differences observed regarding sex, meconium ileus (4.7% vs. 11.1%), dehydration (10.5% vs. 14.7%), or pancreatic insufficiency (PI) (100% vs. 97.8%). The proportion of patients with lung colonization by bacterial pathogens was slightly, but not significantly higher in the R1066C/any mutation group (70.0%), as compared with the ΔF508/ΔF508 group (57.5%). Other clinical complications were significantly more frequent in the R1066C/any mutation patients (P < 0.02) than in the ΔF508/ΔF508 group. The two homozygous R1066C/R1066C patients died at the ages of 3 months and 7 years. The data presented in this study clearly demonstrate that the R1066C mutation is responsible for a severe phenotype similar to that observed in homozygous ΔF508 patients. The poor clinical scores and complications of patients with the R1066C mutation are probably related to their slightly longer survival.

KW - Cystic fibrosis

KW - Genotype/phenotype correlation

KW - R1066C mutation

UR - http://www.scopus.com/inward/record.url?scp=16944365624&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16944365624&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1098-1004(1997)10:5<387::AID-HUMU9>3.0.CO;2-C

DO - 10.1002/(SICI)1098-1004(1997)10:5<387::AID-HUMU9>3.0.CO;2-C

M3 - Article

VL - 10

SP - 387

EP - 392

JO - Human Mutation

JF - Human Mutation

SN - 1059-7794

IS - 5

ER -